Showing 1981-1990 of 3038 results for "".
- Noveome Biotherapeutics Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cellshttps://modernod.com/news/noveome-biotherapeutics-announces-publication-of-further-preclinical-results-supporting-the-neuroprotective-properties-of-st266-in-retinal-ganglion-cells/2476572/Noveome Biotherapeutics announced the publication of preclinical results for ST266, its proprietary, cell-free platform biologic, published in the Journal of Neuro-Ophthalmology. These new results further support the neuroprotective properties of intranasally delivered ST266 in mice with e
- Novartis to Acquire Dry Eye Drug Xiidra in Deal Worth Up to $5.3 Billionhttps://modernod.com/news/novartis-to-acquire-dry-eye-drug-xiidra-in-deal-worth-up-to-5-3-billion/2476567/In one of the largest ophthalmic drug deals to date, Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda Pharmaceutical in a deal worth up to $5.3 billion. Under terms of the deal, Novartis will pay $3.4 billi
- SightGlass Vision Presents Clinical Trial Data From Novel Lenses to Control Myopiahttps://modernod.com/news/sightglass-vision-presents-clinical-trial-data-from-novel-lenses-to-control-myopia/2476541/SightGlass Vision announced that data assessing the tolerability of three iterations of its novel lenses designed to control nearsightedness in children were presented at the Association for Research in Vision and
- Novaliq and BLP Management Group Establish New Company, Betaliq, to Leverage EyeSol Technology to Treat Glaucomahttps://modernod.com/news/novaliq-and-blp-management-group-establish-new-company-betaliq-to-leverage-eyesol-technology-to-treat-glaucoma/2476500/Novaliq and BLP Management group announced the formation and funding of Betaliq. The Tampa-based company’s pipeline consists of two preservative-free glaucoma drug candidates based on new in class and best in class ß-blocker molecules using Novaliq’s waterfree EyeSol technology. Two EyeSol-
- Allegro Expands Its Anti-Integrin Portfolio with New Dry Eye Disease Drug Candidate ALG-1007https://modernod.com/news/allegro-expands-its-anti-integrin-portfolio-with-new-dry-eye-disease-drug-candidate-alg-1007/2476499/Allegro Ophthalmics announced the expansion of the company’s anti-integrin portfolio with the new topical dry eye disease drug candidate ALG-1007. ALG-1007 bolsters Allegro’s existing anti-integrin portfolio, w
- Optos Wins 2019 Queen’s Award for Enterprise Innovationhttps://modernod.com/news/optos-wins-2019-queens-award-for-enterprise-innovation/2476489/UK-based Optos has been recognized for its innovation with a 2019 Queen’s Award for Enterprise. Optos, which has sold more than 16,000 of its ultra-widefield imaging devices to eyecare professionals across the world, won the coveted accolade for the design of its
- Novartis Announces FDA BLA Acceptance of Brolucizumab for Wet AMDhttps://modernod.com/news/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-for-wet-amd/2476468/Novartis announced that the FDA has accepted the company’s biologics license application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD). Novartis used a priority review voucher to expedite FDA review and anticipates launching brolucizumab, if
- NovaBay Pharmaceuticals Announces New Partner Pharmacy Programhttps://modernod.com/news/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/2476465/NovaBay Pharmaceuticals announced a new pharmacy partnering program in an effort to ensure all patients in the United States have reliable and affordable access to prescription Avenova, according to a company news release. NovaBay has recently added six new pharmacies as Avenova channel partners.
- Avedro’s Corneal Cross-Linking Procedure Now Covered by 65 Coverage Policieshttps://modernod.com/news/avedros-corneal-cross-linking-procedure-now-covered-by-65-coverage-policies/2476444/Avedro announced that four new providers—Providence Health Plan in the Pacific Northwest, Health New England, HealthPartners Minnesota, and Public Employees Health Plan (PEHP) in Utah—have issued positive coverage pol
- Alcon Adds Topical Local Anesthetic Alcaine 0.5% 15mL to its Ophthalmic Portfoliohttps://modernod.com/news/alcon-adds-topical-local-anesthetic-alcaine-0-5-15ml-to-its-ophthalmic-portfolio/2476426/Alcon announced the latest addition of Alcaine (proparacaine hydrochloride ophthalmic solution, USP) 0.5% 15mL to its procedural eye drops portfolio, which is made up of mydriatic, cycloplegic, diagnostic, and anesthetic products. Alcaine 0.5% 15mL, the only branded proparacaine available,